ATE216240T1 - Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil - Google Patents

Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil

Info

Publication number
ATE216240T1
ATE216240T1 AT94905024T AT94905024T ATE216240T1 AT E216240 T1 ATE216240 T1 AT E216240T1 AT 94905024 T AT94905024 T AT 94905024T AT 94905024 T AT94905024 T AT 94905024T AT E216240 T1 ATE216240 T1 AT E216240T1
Authority
AT
Austria
Prior art keywords
pct
transdermal therapeutic
therapeutic system
galanthamin
active ingredient
Prior art date
Application number
AT94905024T
Other languages
German (de)
English (en)
Inventor
Thomas Hille
Lothar Deurer
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Application granted granted Critical
Publication of ATE216240T1 publication Critical patent/ATE216240T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
AT94905024T 1993-01-23 1994-01-10 Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil ATE216240T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4301783A DE4301783C1 (de) 1993-01-23 1993-01-23 Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
PCT/EP1994/000054 WO1994016707A1 (fr) 1993-01-23 1994-01-10 Systeme therapeutique transdermique avec de la galanthamine comme composant actif

Publications (1)

Publication Number Publication Date
ATE216240T1 true ATE216240T1 (de) 2002-05-15

Family

ID=6478781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94905024T ATE216240T1 (de) 1993-01-23 1994-01-10 Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil

Country Status (26)

Country Link
US (1) US5700480A (fr)
EP (1) EP0680325B1 (fr)
JP (1) JPH08505632A (fr)
KR (1) KR100300477B1 (fr)
AT (1) ATE216240T1 (fr)
AU (1) AU679032B2 (fr)
CA (1) CA2153572C (fr)
CZ (1) CZ287053B6 (fr)
DE (2) DE4301783C1 (fr)
DK (1) DK0680325T3 (fr)
ES (1) ES2176234T3 (fr)
FI (1) FI113744B (fr)
HR (1) HRP940028B1 (fr)
HU (1) HU221165B1 (fr)
IL (1) IL108235A (fr)
MY (1) MY109926A (fr)
NO (1) NO307497B1 (fr)
NZ (1) NZ259857A (fr)
PH (1) PH31473A (fr)
PL (1) PL175083B1 (fr)
PT (1) PT680325E (fr)
SI (1) SI9400024A (fr)
SK (1) SK281339B6 (fr)
WO (1) WO1994016707A1 (fr)
YU (1) YU48607B (fr)
ZA (1) ZA94414B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429791C2 (de) * 1994-08-23 1997-04-24 Lohmann Therapie Syst Lts Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU732803B2 (en) * 1996-01-17 2001-05-03 National Starch And Chemical Investment Holding Corporation Adhesives resistant to skin-penetration enhancers
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
ES2227707T3 (es) * 1996-07-15 2005-04-01 Alza Corporation Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
DE19649534B4 (de) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
BR9916835A (pt) * 1998-12-24 2001-09-25 Janssen Pharmaceutica Nv Composição de galantamina de liberação controlada
US6241998B1 (en) 1999-02-02 2001-06-05 Acutek International Dermatological patch
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
EP1221315A4 (fr) * 1999-10-13 2007-12-12 Senju Pharma Co Preparation d'adhesif a usage ophtalmique pour l'absorption par voie percutanee
EP2311463A1 (fr) * 1999-12-10 2011-04-20 Bonnie M. Davis Analogues de galanthamine et de lycoramine, utilises en tant que modulateurs des recepteurs nicotiniques
KR101250021B1 (ko) * 2000-05-26 2013-04-03 다이닛본 스미토모 세이야꾸 가부시끼가이샤 완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터
FR2814368B1 (fr) * 2000-09-26 2004-05-07 Pf Medicament Preparation pharmaceutique a base d'oxans
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2551946A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Formulations de galantamine
WO2005065662A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Formulations solides d'administration de galantamine
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
DE602006016441D1 (de) 2005-05-13 2010-10-07 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
WO2007035941A2 (fr) * 2005-09-23 2007-03-29 Alza Corporation Systeme d'administration transdermique de galantamine
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102008059054A1 (de) 2008-11-26 2010-05-27 Otto Bock Pur Life Science Gmbh Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung
EP2640389B1 (fr) 2010-11-17 2014-12-31 Hexal AG Système thérapeutique transdermique comprenant de la buprénorphine
KR101317158B1 (ko) * 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
JP6285820B2 (ja) * 2014-08-07 2018-02-28 久光製薬株式会社 ガランタミン含有経皮吸収製剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone steroide
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
MX2022005168A (es) 2019-11-06 2022-06-08 Smartech Topical Inc Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560710B2 (en) * 1983-04-27 1987-04-16 Lohmann Gmbh & Co. Kg. Pharmaceutical product
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3843239C1 (fr) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
WO1992020327A1 (fr) * 1991-05-14 1992-11-26 Ernir Snorrason Traitement des etats de fatigue a l'aide d'inhibiteurs de cholinesterase

Also Published As

Publication number Publication date
CZ287053B6 (en) 2000-08-16
DE4301783C1 (de) 1994-02-03
NO952907L (no) 1995-07-21
SK88995A3 (en) 1996-05-08
DE59410103D1 (de) 2002-05-23
HRP940028B1 (en) 2000-02-29
HRP940028A2 (en) 1996-06-30
PH31473A (en) 1998-11-03
CA2153572A1 (fr) 1994-08-04
US5700480A (en) 1997-12-23
CA2153572C (fr) 2006-01-03
AU5881794A (en) 1994-08-15
KR100300477B1 (ko) 2001-10-22
YU48607B (sh) 1998-12-23
YU2694A (sh) 1996-10-18
NZ259857A (en) 1996-03-26
FI113744B (fi) 2004-06-15
ES2176234T3 (es) 2002-12-01
EP0680325A1 (fr) 1995-11-08
NO952907D0 (no) 1995-07-21
PT680325E (pt) 2002-09-30
ZA94414B (en) 1994-08-31
NO307497B1 (no) 2000-04-17
SI9400024A (en) 1994-09-30
KR960700060A (ko) 1996-01-19
FI953533A (fi) 1995-07-21
MY109926A (en) 1997-09-30
PL309603A1 (en) 1995-10-30
HU9501928D0 (en) 1995-09-28
PL175083B1 (pl) 1998-10-30
JPH08505632A (ja) 1996-06-18
IL108235A (en) 1996-10-31
DK0680325T3 (da) 2002-08-05
FI953533A0 (fi) 1995-07-21
HU221165B1 (en) 2002-08-28
EP0680325B1 (fr) 2002-04-17
CZ184295A3 (en) 1996-01-17
AU679032B2 (en) 1997-06-19
HUT72643A (en) 1996-05-28
SK281339B6 (sk) 2001-02-12
IL108235A0 (en) 1994-04-12
WO1994016707A1 (fr) 1994-08-04

Similar Documents

Publication Publication Date Title
ATE216240T1 (de) Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
ES2105334T3 (es) Sistema terapeutico percutaneo para la administracion de fisostigmina en la piel y el procedimiento para su obtencion.